HC Wainwright Issues Pessimistic Forecast for Curis (NASDAQ:CRIS) Stock Price

Curis (NASDAQ:CRIS) had its target price decreased by HC Wainwright from $26.00 to $20.00 in a research report released on Friday morning, Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

Curis Stock Down 2.3 %

Shares of NASDAQ:CRIS traded down $0.10 during trading on Friday, reaching $4.18. 40,502 shares of the company traded hands, compared to its average volume of 37,330. Curis has a 52 week low of $4.05 and a 52 week high of $17.49. The firm has a market capitalization of $25.00 million, a PE ratio of -0.51 and a beta of 3.32. The company’s 50 day moving average is $5.28 and its two-hundred day moving average is $7.86.

Curis (NASDAQ:CRIS) last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($2.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.36). Curis had a negative return on equity of 327.92% and a negative net margin of 468.18%. The firm had revenue of $2.55 million for the quarter, compared to analyst estimates of $2.20 million. During the same quarter in the previous year, the company earned ($2.40) earnings per share. As a group, research analysts anticipate that Curis will post -6.79 EPS for the current year.

Hedge Funds Weigh In On Curis

A number of institutional investors have recently modified their holdings of CRIS. Focused Wealth Management Inc boosted its stake in Curis by 63.1% in the third quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock valued at $291,000 after buying an additional 20,908 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in shares of Curis by 795.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock valued at $748,000 after purchasing an additional 96,256 shares during the last quarter. CM Management LLC increased its position in Curis by 380.0% during the 1st quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock worth $1,304,000 after purchasing an additional 95,000 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Curis by 4.8% in the 1st quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock valued at $2,376,000 after purchasing an additional 10,097 shares during the last quarter. Institutional investors and hedge funds own 29.97% of the company’s stock.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.